Emergence of topical treatments are creating incremental opportunities for manufacturers operating in the optic nerve disorders treatment market. For instance, Canadian manufacturers of eye health products Bausch & Lomb, announced the launch of VYZULTA® — a topical glaucoma treatment solution that gained acceptance by the Government of Canada.
Companies in the optic nerve disorders treatment market are increasing treatment options for glaucoma, since the glaucoma indication segment of the optic nerve disorders treatment market is projected for exponential growth during the forecast period. The glaucoma segment is expected to reach a value of ~US$ 12.1 Bn by the end of 2023. Hence, manufacturers are increasing efficacy in precision medication to offer treatment options for glaucoma.
To innovate in precision medicines, manufacturers in the market for optic nerve disorders treatment are increasing research to understand the aqueous humor for anterior segment and trabecular meshwork tissue.
High prevalence of multiple sclerosis (MS) patients is one of the key drivers for the growth of optic nerve disorders treatment market. Hence, manufacturers are increasing production capabilities to develop immunosuppressive drugs that improve quality of life in patients. For instance, in September 2019, Swiss multinational healthcare company Roche revealed its proceedings on trials for OCREVUS® — an immunosuppressive drug, to understand its effects in relapsing and progressive MS.
Companies in the optic nerve disorders treatment market are increasing trials of immunosuppressive drugs with beta interferons to provide relief to MS patients. As such, the beta interferons sub-segment of the pharmacological treatment segment is estimated to reach a value of ~US$ 2.5 Bn by 2027. Hence, manufacturers in the optic nerve disorders treatment market are increasing production capabilities in beta interferons, since pharmacological treatment segment is anticipated for aggressive growth during the forecast period. Moreover, the neurofilament light chain-lowering capabilities of beta interferons are increasingly benefitting MS patients.
New drugs for rare neurologic eye diseases are being extensively researched for the treatment of MS and neuromyelitis optica. Striking correlation between neurologic diseases and rare eye conditions have opened the doors for innovation in the optic nerve disorders treatment market.
On the other hand, terminal complement inhibitors are under scrutiny of the European and Japanese health commissions. As such, companies are focusing to extend their product portfolios into Europe and Japan, since the two regions are projected for exponential growth during the forecast period. For instance, in June 2019, Alexion — a U.S. pharmaceutical company, announced that the European Medicines Agency and Japanese Ministry of Health, Labor and Welfare are assessing applications of SOLIRIS® for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
The optic nerve disorders treatment market in Europe is expected to reach a value of ~US$ 4.2 Bn. Thus, manufacturers in the market for optic nerve disorders treatment are focusing on meeting the needs of patients in Europe, since NMOSD is a rare disease.
Innovations in topical ocular corticosteroids are proving to be beneficial for patients in the management of pain and inflammation post ocular surgery. However, limitations of these corticosteroids, such as limited bioavailability and class-associated adverse events (AE) are some of the barriers that companies in the optic nerve disorders treatment market have to counter. Hence, manufacturers in the optic nerve disorders treatment market are educating healthcare providers about drug-specific variables of topical ocular corticosteroids, such as AE profile, potency, and patient-specific administration needs for better outcomes in patients.
Companies in the market for optic nerve disorders treatment are aiming at minimizing precorneal drug loss and maximizing drug delivery to the anterior tissues with the help of improved corticosteroid formulations. They are adopting various strategies to enhance ocular penetration by including mucoadhesive formulations in the development of new corticosteroids. Strategies, such as drug-particle size reduction enable faster drug dissolution, which increases bioavailability and penetration. Hence, companies in the optic nerve disorders treatment market are increasing the production capacities of loteprednol etabonate corticosteroids using retrometabolic drug design.
Analysts’ Viewpoint
Companies in the optic nerve disorders treatment market are tapping into new opportunities to obtain new clues from drugs used in neurological disorders for treatment of vision-related diseases. For instance, in May 2019, Bionure — a Spanish biotechnology company, announced its successful investigation for its neuroprotectant BN201, which holds promising results in the treatment of MS and acute optic neuritis.
However, poor bioavailability of drugs for efficacious ocular drug delivery poses as a challenge for manufacturers. Hence, companies should innovate in ocular therapeutics to improve biopharmaceutical properties of drugs. They should focus on expanding product portfolio of drugs that treat optic neuritis, since this indication is projected to gain significant prominence during the forecast period.
Optic nerve disorders treatment market to reach a valuation of ~US$ 19.5 Bn by 2027
Optic nerve disorders treatment market is expected to expand at a CAGR of ~4% during the forecast period from 2019 to 2027
Optic nerve disorders treatment market is driven by increase in prevalence of eye disorders
North America accounted for a major share of the optic nerve disorders treatment market, and is projected to remain dominant during the forecast period
Key players in the global optic nerve disorders treatment market include Santen Pharmaceutical Co., Ltd., Allergan plc. Novartis AG, Pfizer, Inc., Bausch Health Companies
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Optic Nerve Disorders Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Treatment Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Vendor and Distributor Analysis
5.3. Technological Advancements
5.4. Prevalence & Incidence of Optic Nerve Disorders
5.5. Regulatory Scenario Assessment
6. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Treatment Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Treatment Type, 2017–2027
6.3.1. Pharmacological Treatment
6.3.1.1. Prostaglandins
6.3.1.2. Beta Interferons
6.3.1.3. Beta Blockers
6.3.1.4. Alpha-adrenergic Agonist
6.3.1.5. Carbonic Anhydrase Inhibitors
6.3.1.6. Corticosteroids
6.3.1.7. Combination Drugs
6.3.1.8. Others
6.3.2. Surgery
6.4. Market Attractiveness By Treatment Type, 2019-2027
7. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Indication
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Indication, 2017–2027
7.3.1. Glaucoma
7.3.2. Optic Neuritis
7.3.3. Optic Neuropathy
7.3.3.1. Arteritic ischemic optic neuropathy
7.3.3.2. Non-arteritic ischemic optic neuropathy
7.3.3.3. Congenital Optic Atrophy
7.3.4. Others
7.4. Market Attractiveness By Indication, 2019-2027
8. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2017–2027
8.3.1. Hospitals
8.3.2. Ambulatory Surgery Centers
8.3.3. Clinics
8.3.4. Others
8.4. Market Attractiveness By End-user, 2019-2027
9. Global Optic Nerve Disorders Treatment Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region, 2019-2027
10. North America Optic Nerve Disorders Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Treatment Type, 2017–2027
10.2.1. Pharmacological Treatment
10.2.1.1. Prostaglandins
10.2.1.2. Beta Interferons
10.2.1.3. Beta Blockers
10.2.1.4. Alpha-adrenergic Agonist
10.2.1.5. Carbonic Anhydrase Inhibitors
10.2.1.6. Corticosteroids
10.2.1.7. Combination Drugs
10.2.1.8. Others
10.2.2. Surgery
10.3. Market Value Forecast By Indication, 2017–2027
10.3.1. Glaucoma
10.3.2. Optic Neuritis
10.3.3. Optic Neuropathy
10.3.3.1. Arteritic ischemic optic neuropathy
10.3.3.2. Non-arteritic ischemic optic neuropathy
10.3.3.3. Congenital Optic Atrophy
10.3.4. Others
10.4. Market Value Forecast By End-user, 2017–2027
10.4.1. Hospitals
10.4.2. Ambulatory Surgery Centers
10.4.3. Clinics
10.4.4. Others
10.5. Market Value Forecast By Country, 2017–2027
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment Type
10.6.2. By Indication
10.6.3. By End-user
10.6.4. By Country
11. Europe Optic Nerve Disorders Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast by Treatment Type, 2017–2027
11.2.1. Pharmacological Treatment
11.2.1.1. Prostaglandins
11.2.1.2. Beta Interferons
11.2.1.3. Beta Blockers
11.2.1.4. Alpha-adrenergic Agonist
11.2.1.5. Carbonic Anhydrase Inhibitors
11.2.1.6. Corticosteroids
11.2.1.7. Combination Drugs
11.2.1.8. Others
11.2.2. Surgery
11.3. Market Value Forecast by Indication, 2017–2027
11.3.1. Glaucoma
11.3.2. Optic Neuritis
11.3.3. Optic Neuropathy
11.3.3.1. Arteritic ischemic optic neuropathy
11.3.3.2. Non-arteritic ischemic optic neuropathy
11.3.3.3. Congenital Optic Atrophy
11.3.4. Others
11.4. Market Value Forecast by End-user, 2017–2027
11.4.1. Hospitals
11.4.2. Ambulatory Surgery Centers
11.4.3. Clinics
11.4.4. Others
11.5. Market Value Forecast by Country/Sub-region, 2017–2027
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment Type
11.6.2. By Indication
11.6.3. By End-user
11.6.4. By Country
12. Asia Pacific Optic Nerve Disorders Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast by Treatment Type, 2017–2027
12.2.1. Pharmacological Treatment
12.2.1.1. Prostaglandins
12.2.1.2. Beta Interferons
12.2.1.3. Beta Blockers
12.2.1.4. Alpha-adrenergic Agonist
12.2.1.5. Carbonic Anhydrase Inhibitors
12.2.1.6. Corticosteroids
12.2.1.7. Combination Drugs
12.2.1.8. Others
12.2.2. Surgery
12.3. Market Value Forecast by Indication, 2017–2027
12.3.1. Glaucoma
12.3.2. Optic Neuritis
12.3.3. Optic Neuropathy
12.3.3.1. Arteritic ischemic optic neuropathy
12.3.3.2. Non-arteritic ischemic optic neuropathy
12.3.3.3. Congenital Optic Atrophy
12.3.4. Others
12.4. Market Value Forecast by End-user, 2017–2027
12.4.1. Hospitals
12.4.2. Ambulatory Surgery Centers
12.4.3. Clinics
12.4.4. Others
12.5. Market Value Forecast by Country/Sub-region, 2017–2027
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment Type
12.6.2. By Indication
12.6.3. By End-user
12.6.4. By Country
13. Latin America Optic Nerve Disorders Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast by Treatment Type, 2017–2027
13.2.1. Pharmacological Treatment
13.2.1.1. Prostaglandins
13.2.1.2. Beta Interferons
13.2.1.3. Beta Blockers
13.2.1.4. Alpha-adrenergic Agonist
13.2.1.5. Carbonic Anhydrase Inhibitors
13.2.1.6. Corticosteroids
13.2.1.7. Combination Drugs
13.2.1.8. Others
13.2.2. Surgery
13.3. Market Value Forecast by Indication, 2017–2027
13.3.1. Glaucoma
13.3.2. Optic Neuritis
13.3.3. Optic Neuropathy
13.3.3.1. Arteritic ischemic optic neuropathy
13.3.3.2. Non-arteritic ischemic optic neuropathy
13.3.3.3. Congenital Optic Atrophy
13.3.4. Others
13.4. Market Value Forecast by End-user, 2017–2027
13.4.1. Hospitals
13.4.2. Ambulatory Surgery Centers
13.4.3. Clinics
13.4.4. Others
13.5. Market Value Forecast By Country/Sub-region, 2017–2027
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment Type
13.6.2. By Indication
13.6.3. By End-user
13.6.4. By Country
14. Middle East & Africa Optic Nerve Disorders Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast by Treatment Type, 2017–2027
14.2.1. Pharmacological Treatment
14.2.1.1. Prostaglandins
14.2.1.2. Beta Interferons
14.2.1.3. Beta Blockers
14.2.1.4. Alpha-adrenergic Agonist
14.2.1.5. Carbonic Anhydrase Inhibitors
14.2.1.6. Corticosteroids
14.2.1.7. Combination Drugs
14.2.1.8. Others
14.2.2. Surgery
14.3. Market Value Forecast by Indication, 2017–2027
14.3.1. Glaucoma
14.3.2. Optic Neuritis
14.3.3. Optic Neuropathy
14.3.3.1. Arteritic ischemic optic neuropathy
14.3.3.2. Non-arteritic ischemic optic neuropathy
14.3.3.3. Congenital Optic Atrophy
14.3.4. Others
14.4. Market Value Forecast by End-user, 2017–2027
14.4.1. Hospitals
14.4.2. Ambulatory Surgery Centers
14.4.3. Clinics
14.4.4. Others
14.5. Market Value Forecast by Country/Sub-region, 2017–2027
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment Type
14.6.2. By Indication
14.6.3. By End-user
14.6.4. By Country
15. Competition Landscape
15.1. Market Player – Competition Matrix (By Tier and Size of companies)
15.2. Market Position/Ranking Analysis, By Tier and Size of the Company (2018)
15.3. Company Profiles
15.3.1. Santen Pharmaceutical Co., Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Company Financials
15.3.1.3. Growth Strategies
15.3.1.4. SWOT Analysis
15.3.2. Allergan plc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Company Financials
15.3.2.3. Growth Strategies
15.3.2.4. SWOT Analysis
15.3.3. Novartis AG
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Company Financials
15.3.3.3. Growth Strategies
15.3.3.4. SWOT Analysis
15.3.4. Pfizer, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Company Financials
15.3.4.3. Growth Strategies
15.3.4.4. SWOT Analysis
15.3.5. Bausch Health Companies, Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Company Financials
15.3.5.3. Growth Strategies
15.3.5.4. SWOT Analysis
15.3.6. Aerie Pharmaceuticals, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Company Financials
15.3.6.3. Growth Strategies
15.3.6.4. SWOT Analysis
15.3.7. Teva Pharmaceutical Industries Ltd.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Company Financials
15.3.7.3. Growth Strategies
15.3.7.4. SWOT Analysis
15.3.8. Bionure Farma, S.L.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Company Financials
15.3.8.3. Growth Strategies
15.3.8.4. SWOT Analysis
15.3.9. Mallinckrodt Pharmaceuticals
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Company Financials
15.3.9.3. Growth Strategies
15.3.9.4. SWOT Analysis
List of Tables
Table 01: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 02: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027
Table 03: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 04: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027
Table 05: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 06: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
Table 07: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
Table 08: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 09: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027
Table 10: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 11: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027
Table 12: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 13: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 14: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 15: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027
Table 16: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 17: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027
Table 18: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 19: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 20: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 21: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027
Table 22: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 23: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027
Table 24: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 25: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 26: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 27: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027
Table 28: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 29: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027
Table 30: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
Table 31: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
Table 32: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Treatment Type, 2017–2027
Table 33: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Pharmacological Treatment, 2017–2027
Table 34: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Indication, 2017–2027
Table 35: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by Optic Neuropathy, 2017–2027
Table 36: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, by End-user, 2017–2027
List of Figures
Figure 01: Global Optic Nerve Disorders Treatment Market Size (US$ Mn) and Distribution, by Region, 2018 and 2027
Figure 02: Global Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast, 2017–2027
Figure 03: Global Optic Nerve Disorders Treatment Market Value Share, by Treatment Type (2018)
Figure 04: Global Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment (2018)
Figure 05: Global Optic Nerve Disorders Treatment Market Value Share, by Indication (2018)
Figure 06: Global Optic Nerve Disorders Treatment Market Value Share, by End-user (2018)
Figure 07: Global Optic Nerve Disorders Treatment Market Value Share, by Region (2018)
Figure 08: Regulatory Approval Process - The U.S.
Figure 09: Regulatory Approval Process - Europe
Figure 10: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Treatment Type, 2018 and 2027
Figure 11: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Pharmacological Treatment, 2018 and 2027
Figure 12: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Pharmacological Treatment, 2017–2027
Figure 13: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Surgery, 2017–2027
Figure 14: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Prostaglandins, 2017-2027
Figure 15: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Interferons, 2017-2027
Figure 16: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Beta Blockers, 2017-2027
Figure 17: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Alpha-adrenergic agonist, 2017-2027
Figure 18: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Carbonic Anhydrase Inhibitors, 2017-2027
Figure 19: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Corticosteroidss, 2017-2027
Figure 20: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Combination Drugs, 2017-2027
Figure 21: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
Figure 22: Global Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 23: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by Indication, 2018 and 2027
Figure 24: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Glaucoma, 2017-2027
Figure 25: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Optic Neuritis, 2017-2027
Figure 26: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Optic Neuropathy, 2017-2027
Figure 27: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2017-2027
Figure 28: Global Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027
Figure 29: Global Optic Nerve Disorders Treatment Market Value Share Analysis, by End-user, 2018 and 2027
Figure 30: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospitals, 2017–2027
Figure 31: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Ambulatory Surgery Centers, 2017–2027
Figure 32: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2017–2027
Figure 33: Global Optic Nerve Disorders Treatment Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Academic & Research Institutes, 2017–2027
Figure 34: Global Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027
Figure 35: Global Optic Nerve Disorders Treatment Market Value Share, by Region, 2018 and 2027
Figure 36: Global Optic Nerve Disorders Treatment Market Attractiveness, by Region, 2019–2027
Figure 37: North America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 38: North America Optic Nerve Disorders Treatment Market Value Share, by Country, 2018 and 2027
Figure 39: North America Optic Nerve Disorders Treatment Market Attractiveness, by Country, 2019–2027
Figure 40: North America Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 41: North America Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027
Figure 42: North America Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027
Figure 43: North America Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027
Figure 44: North America Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027
Figure 45: North America Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027
Figure 46: North America Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027
Figure 47: Europe Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 48: Europe Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 49: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 50: Europe Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 51: Europe Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027
Figure 52: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027
Figure 53: Europe Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027
Figure 54: Europe Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027
Figure 55: Europe Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027
Figure 56: Europe Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027
Figure 57: Asia Pacific Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 58: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 59: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 60: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 61: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027
Figure 62: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Treatment type, 2019–2027
Figure 63: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027
Figure 64: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027
Figure 65: Asia Pacific Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027
Figure 66: Asia Pacific Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027
Figure 67: Latin America Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 68: Latin America Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 69: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 70: Latin America Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 71: Latin America Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027
Figure 72: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 73: Latin America Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027
Figure 74: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027
Figure 75: Latin America Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027
Figure 76: Latin America Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027
Figure 77: Middle East & Africa Optic Nerve Disorders Treatment Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2027
Figure 78: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
Figure 79: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
Figure 80: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Treatment Type, 2018 and 2027
Figure 81: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Pharmacological Treatment, 2018 and 2027
Figure 82: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Treatment Type, 2019–2027
Figure 83: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by Indication, 2018 and 2027
Figure 84: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by Indication, 2019–2027
Figure 85: Middle East & Africa Optic Nerve Disorders Treatment Market Value Share, by End-user, 2018 and 2027
Figure 86: Middle East & Africa Optic Nerve Disorders Treatment Market Attractiveness, by End-user, 2019–2027
Figure 87: Market Position/Ranking Analysis, 2018, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Optic Nerve Disorders Treatment Market
